
COMPASS Pathways (CMPS) Stock Forecast & Price Target
COMPASS Pathways (CMPS) Analyst Ratings
Bulls say
Compass Pathways PLC is focused on addressing treatment-resistant depression (TRD) through its innovative psilocybin therapy, COMP360, which has shown significant efficacy in clinical trials with strong data supporting long-lasting improvements in patient outcomes. The company's recent Phase III clinical trials indicate a durable response in patients, with notable improvements in the Montgomery-Åsberg Depression Rating Scale (MADRS) scores and evidence that redosing enhances therapeutic benefits. Enhanced familiarity with regulatory pathways for psychedelics and increasing patient demand position Compass Pathways favorably for potential FDA approval and successful commercialization, suggesting significant upside potential for the company's stock in the future.
Bears say
Compass Pathways PLC faces significant risks that could adversely affect its stock performance, particularly concerning its COMP360 psilocybin therapy and other pipeline programs. Key concerns include the failure of COMP360 to demonstrate clinically meaningful benefits in upcoming Phase III trials, potential safety signals, and challenges in commercializing the product, all of which could see the stock decline sharply. Additionally, the company's non-revenue-generating status, combined with broader investor caution regarding the psychedelic space and commercialization uncertainties, further contributes to a negative outlook for the stock.
This aggregate rating is based on analysts' research of COMPASS Pathways and is not a guaranteed prediction by Public.com or investment advice.
COMPASS Pathways (CMPS) Analyst Forecast & Price Prediction
Start investing in COMPASS Pathways (CMPS)
Order type
Buy in
Order amount
Est. shares
0 shares